Silvermack Therapeutics To Present Data From Phase 1/1b Clinical Trial Of SBT6050 At European Society For Medical Oncology 2021 Virtual Congress
Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 1)
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 26)
SVB Leerink Maintains Outperform on Silverback Therapeutics, Raises Price Target to $49
SVB Leerink analyst Daina Graybosch maintains Silverback Therapeutics (NASDAQ:SBTX) with a Outperform and raises the price target from $46 to $49.
Silverback Therapeutics Q2 EPS $(0.70) Up From $(9.65) YoY
Silverback Therapeutics (NASDAQ:SBTX) reported quarterly losses of $(0.70) per share. This is a 92.75 percent increase over losses of $(9.65) per share from the same period last year.
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo, Initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers
Silverback Therapeutics, Inc. (NASDAQ:SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue
JonesTrading Initiates Coverage On Silverback Therapeutics with Buy Rating, Announces Price Target of $50
JonesTrading analyst Soumit Roy initiates coverage on Silverback Therapeutics (NASDAQ:SBTX) with a Buy rating and announces Price Target of $50.
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 13)